Two-phase teratology study with the synthetic prostaglandin ONO-802 given intravaginally to rats.
The synthetic prostaglandin ONO-802 was administered intravaginally to Sprague Dawley rats at doses of 1.0, 0.5, and 0.125 mg/kg on days 6 through 15 of gestation. A vehicle control group was treated with pessaries that did not contain the drug while another group remained untreated. Body weight, food, water consumption, and clinical signs were monitored during the experiment. In Phase One, 20 pregnant animals from each group were sacrificed at term, major organs were weighted, and litter and fetal data were collected. In Phase Two ten dams per group were allowed to deliver their litters, and the offspring were evaluated for survival, growth, developmental signs, and physiological function. Selected F1 offspring were retained to assess learning and emotional behavior or reproductive capacity. Administration of either 0.5 or 1.0 mg/kg of ONO-802 resulted in a slight reduction in food consumption and body weight gain. Water consumption was increased both during and after the dosing period for the mid and high dose dams. Significantly increased weights for the heart, lungs, liver, adrenals, and ovaries and decreased weights for the thymus gland were noted at term sacrifice of the 1.0 mg/kg dams, whereas the 0.5 mg/kg group had increased weights of the adrenals and ovaries only. Litter parameters were unaffected by treatment. Weights of the female fetuses of the 1.0 and 0.5 mg/kg groups were significantly reduced when compared to controls. There were no significant drug-related abnormalities among the F1 offspring and no evidence that treatment of the F0 dams affected the development, behavior, or reproductive performance of the F1 offspring. Thus, ONO-802 was not teratogenic when given to rats by the intravaginal route.
D000019:Abortifacient Agents / Q000633:toxicity*; D000020:Abortifacient Agents, Nonsteroidal / Q000633:toxicity*; D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D010064:Embryo Implantation / Q000187:drug effects; D004822:Epididymis / Q000187:drug effects; D005260:Female; D005313:Fetal Death; D008098:Litter Size / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000187:drug effects; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D013723:Teratogens; D013737:Testis / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; D013723:Teratogens; C021182:gemeprost; D000527:Alprostadil